TPM Vol. 32, No. S5, 2025
ISSN: 1972-6325
https://www.tpmap.org/

Open Access

CLINICAL APPLICATIONS OF LABORATORY BIOMARKERS IN EARLY DISEASE DETECTION: AN UPDATED REVIEW

MANAL AHMED ALKHARASHI[1], ABDULLAH AYAD ABDULAZIZ ALAUJAN[2], HAMAD OTHMAN AL-ESSA[3], JAMAL EID ALSHANWANY[4], SAAD ALI SOULAN[5], MOHAMMED MAJBUR AWAJI[6], MESHAL MAHDI ABDULRAHMAN ALSHEHRI[7], BASEM AHMED ALSHEBAYLI[8], WJDAN HAMAD ALSANI[9], AMINAH AHMAD ALZAILAI[10], ADWA RASHED ALMSAARI[11], ALANOOD NOORI ALOBAID[12], AISHA ALWALEED ALROOMI[13], FAISAL THANI ALANAZI[14], SAEED MOHAMMED MOUSA[15]

[1] LABORATORY TECHNICIAN, KING KHALID UNIVERSITY HOSPITAL, SAUDI ARABIA. EMAIL: malkharashi1@ksu.edu.sa -
[2] LABORATORY SPECIALIST, MEDICAL LAB - KKUH, SAUDI ARABIA. EMAIL: alaujan.abdullah@gmail.com -
[3] MEDICAL SECRETARY, KING KHALID UNIVERSITY HOSPITAL, SAUDI ARABIA. EMAIL: sag.313@hotmail.com
[4] LABORATORY SPECIALIST, KING SAUD UNIVERSITY - KING KHALID UNIVERSITY HOSPITAL, SAUDI ARABIA. EMAIL: jalshanwani@ksu.edu.sa
[5] MEDICAL SECRETARY, KING KHALID UNIVERSITY HOSPITAL, SAUDI ARABIA. EMAIL: salsoulan@ksu.edu.sa
[6] LABORATORY TECHNICIAN, KING SAUD UNIVERSITY, SAUDI ARABIA. EMAIL: mawaji@ksu.edu.sa
[7] LAB SPECIALIST, KING SAUD UNIVERSITY - COLLEGE OF MEDICINE, SAUDI ARABIA. EMAIL: almeshal@ksu.edu.sa
[8] LAB TECHNICIAN, KING KHALID UNIVERSITY HOSPITAL, SAUDI ARABIA. EMAIL: basooom33@hotmail.com -
[9] LABORATORY TECHNICIAN, KING KHALID UNIVERSITY HOSPITAL, SAUDI ARABIA. EMAIL: wjdan_al@hotmail.com - SCFHS: 14RT0008348
[10] LECTURER, DEPARTMENT OF CLINICAL LABORATORY SCIENCES (CLS), COLLEGE OF APPLIED MEDICAL SCIENCES, KING SAUD UNIVERSITY, SAUDI ARABIA. EMAIL: amalzailai@ksu.edu.sa - SCFHS: 09RA0260597
[11] PHLEBOTOMIST, KING KHALID MEDICAL CITY, SAUDI ARABIA. EMAIL: A.almsaari@hotmail.com
[12] PHLEBOTOMIST, KING SAUD UNIVERSITY MEDICAL CITY, SAUDI ARABIA. EMAIL: aalobaid3@ksu.edu.sa -
[13] LABORATORY TECHNOLOGIST, KING KHALID UNIVERSITY HOSPITAL, SAUDI ARABIA. EMAIL: aishawalroomi@gmail.com
[14] TECHNICIAN PHARMACY, DEPARTMENT OF PHARMACY, KING SAUD UNIVERSITY MEDICAL CITY, RIYADH, SAUDI ARABIA. EMAIL: afaysal@ksu.edu.sa
[15] TECHNICIAN PHARMACY, KING ABDULAZIZ UNIVERSITY HOSPITAL, SAUDI ARABIA. EMAIL: smousa@ksu.edu.sa

Abstract
The paradigm of modern medicine is shifting from reactive treatment to proactive and pre-emptive intervention, a transition fundamentally enabled by the discovery and clinical application of novel laboratory biomarkers. This narrative review synthesizes recent advancements from 2015 to 2026 in the utilization of circulating and genomic biomarkers for early disease detection across key clinical domains, including oncology, neurodegenerative disorders, cardiovascular diseases, and infectious diseases. We critically examine the evolution of liquid biopsies, comprising circulating tumor DNA, circulating tumor cells, and exosomes, which have revolutionized early cancer detection and minimal residual disease monitoring. In neurodegenerative diseases like Alzheimer's, we explore the diagnostic accuracy of blood-based phospho-tau species and neurofilament light chain, which now approximate the performance of positron emission tomography and cerebrospinal fluid assays. For cardiovascular risk stratification, the integration of high-sensitivity cardiac troponins, natriuretic peptides, and novel inflammatory markers into polygenic risk scores is redefining primary prevention. The review also addresses the systemic challenges of clinical implementation, including the interpretive complexity of multi-marker panels, standardization across analytical platforms, and the ethical management of preclinical disease states. By highlighting the convergence of multi-omics and artificial intelligence, we outline a future where comprehensive biomarker profiling defines a new taxonomy of human disease, enabling truly personalized and anticipatory healthcare.

Keywords: Liquid Biopsy, Early Cancer Detection, Alzheimer's Disease Biomarkers, High-Sensitivity Troponin, Multi-Omics Integration

1. INTRODUCTION

The relentless pursuit of extending human healthspan hinges on a singular, critical juncture: the ability to detect disease before its clinical manifestation. For centuries, diagnosis has been a retrospective art, dependent on the patient's narrative of symptoms and the physician's recognition of syndromic patterns. This paradigm, however, is inherently constrained, often intervening at a point of no return where pathological cascades are entrenched and tissue damage is irreversible. The 21st century has witnessed a transformative disruption of this model, catalyzed by the molecular biology revolution and the advent of high-throughput omics technologies (Ashley, 2016). The modern concept of the laboratory biomarker, once limited to simple biochemical assays like glucose or cholesterol, has expanded into a universe of dynamic, multi-analyte signatures that reflect the genome, transcriptome, proteome, and metabolome. These biomarkers are no longer mere correlates of disease; they are powerful prognosticators and predictive tools that offer a window into the presymptomatic phase of illness, fundamentally redefining the therapeutic window of opportunity (Karczewski & Snyder, 2018).

This evolution is most palpable in the shift from tissue-dependent diagnostics to minimally invasive liquid biopsies, a transition that has demolished barriers to serial sampling and population-level screening (Ignatiadis, Sledge, & Jeffrey, 2021). The detection of circulating tumor DNA (ctDNA) fragments, circulating tumor cells (CTCs), and extracellular vesicles in a simple blood draw has turned the peripheral blood compartment into a comprehensive, real-time biopsy of solid tumors and hematological malignancies alike. Parallel to this oncological revolution, the field of neurology has experienced its own paradigm shift, as blood-based biomarkers for Alzheimer's disease (AD) have shattered the long-held dependence on cerebrospinal fluid (CSF) analysis and costly amyloid positron emission tomography (PET) imaging, promising to democratize access to early and accurate diagnosis (Hansson et al., 2022). In cardiology, the incremental refinement of biomarkers like high-sensitivity cardiac troponin (hs-cTn) has allowed for the detection of subclinical myocardial injury in asymptomatic populations, effectively creating a new category of pre-heart failure risk stratification that challenges traditional primary prevention algorithms (Zeller et al., 2015). Figure 1 illustrates the integration of genomic, transcriptomic, proteomic, metabolomic, and microbiome biomarkers through artificial intelligence enables precision medicine by improving early disease detection, individualized risk prediction, and personalized therapeutic decision-making.



Figure 1. Multi-Omics Biomarker Pipeline for Early Disease Detection.

Yet, this flood of biological data presents a formidable paradox: the more we measure, the more complex clinical interpretation becomes. The integration of thousands of data points per patient necessitates a departure from univariate analysis to sophisticated machine learning and artificial intelligence (AI) algorithms that can discern non-linear, multi-dimensional patterns invisible to the human eye (Topol, 2019). This review aims to provide a synthetic and critical narrative of the clinical applications of laboratory biomarkers for early disease detection over the past decade (2015–2026). We will traverse the major clinical arenas where these technologies have made the most significant inroads, analyzing their diagnostic accuracy, clinical utility, and the systemic hurdles that impede their translation from discovery to standard of care. Finally, we will explore the ethical and epistemological challenges of identifying disease in the healthy, a paradigm that necessitates a new social contract between medicine and society.

2. The Liquid Biopsy Revolution in Oncology

No field has been as profoundly reshaped by molecular biomarkers as oncology. The traditional diagnostic pathway, reliant on invasive tissue biopsies, is fraught with limitations including sampling bias due to tumor heterogeneity, procedural risk, and the impracticality of longitudinal monitoring (Gorgannezhad et al., 2018). The liquid biopsy has emerged as a transformative solution, offering a non-invasive, serial, and holistic view of tumor biology. The core analytes—ctDNA, CTCs, and exosomes—each provide a distinct perspective on the tumor's identity, burden, and dynamic evolution. An overview of the key circulating biomarkers discussed across clinical domains, their diagnostic performance metrics, and their current stage of clinical application is provided in Table 1.

Table 1. Key Circulating Biomarkers for Early Disease Detection: Performance and Clinical Application

Biomarker Class	Specific Analyte	Primary Disease Focus	Key Diagnostic Metric / Performance	Current Clinical Application Stage
Liquid Biopsy (ctDNA)	Methylated ctDNA panel	Multi-Cancer (50+ types)	99.5% Specificity; 93% Tissue-of-Origin Accuracy; ~38% PPV (Liu et al., 2020; Klein et al., 2022)	Population screening (clinical trials/non-FDA cleared); MRD monitoring (FDA cleared)
Liquid Biopsy (CTC)	EpCAM+/CK+ CTCs	Metastatic Breast, Prostate, Colorectal Cancer	≥5 cells/7.5mL blood → poor PFS (HR 2.5-4.0) (Cristofanilli et al., 2019)	FDA-cleared for prognostic monitoring; therapeutic guidance (characterization) under investigation
Neurodegeneration	Plasma p-tau217	Alzheimer's Disease	AUC ~0.98 for AD vs. controls; superior to CSF and plasma p-tau181 (Palmqvist et al., 2020)	Clinical diagnostic triage; used in therapeutic trial screening (e.g., for lecanemab)
Neurodegeneration	Serum Neurofilament Light (NfL)	Multiple Sclerosis, ALS, General Neuroaxonal Injury	Correlates with MRI lesions in MS (r=0.6); strong predictor of survival in ALS (HR 2.3) (Kuhle et al., 2019; Benatar et al., 2023)	Clinical disease monitoring and trial endpoint (MS); prognostic counseling (ALS)
Cardiovascular	High-sensitivity Cardiac Troponin I (hs-cTnI)	Preclinical Myocardial Injury, Primary Prevention	Above limit of detection in 25% of healthy middle-aged adults; independent predictor of 15-yr CV death (HR 2.1) (Jia et al., 2019)	Guideline-recommended for AMI diagnosis; emerging for primary prevention risk reclassification
Cardiovascular	NT-proBNP	Preclinical Heart Failure	Screening + collaborative care reduced LV systolic dysfunction by 45% (Ledwidge et al., 2013)	Guideline-recommended for HF diagnosis; guided primary prevention in high-risk cohorts
Cardiovascular	Coronary Artery Disease Polygenic Risk Score (PRS)	Coronary Artery Disease	High PRS confers 3-fold increased risk, comparable to FH; identifies statin benefit (Khera et al., 2018)	Clinical risk calculators and direct-to-consumer testing; integrated into integrative personal profiles

Note: AUC = Area Under the Curve; PPV = Positive Predictive Value; HR = Hazard Ratio; PFS = Progression-Free Survival; FH = Familial Hypercholesterolemia.

2.1 Circulating Tumor DNA: From Minimal Residual Disease to Multi-Cancer Screening

Circulating tumor DNA consists of short DNA fragments shed into the bloodstream through tumor cell apoptosis, necrosis, and active secretion. Its half-life of less than two hours makes it an exquisitely real-time indicator of

tumor presence and response to therapy (Wan et al., 2017). The clinical applications of ctDNA analysis are stratified along the cancer care continuum, but its most profound impact has been in the realms of early detection and minimal residual disease (MRD) assessment. MRD, defined as the persistence of ctDNA after curative-intent therapy, often precedes radiographic recurrence by several months, providing a critical window for therapeutic escalation. In colorectal cancer, the DYNAMIC trial demonstrated that a ctDNA-guided approach to adjuvant chemotherapy reduced the proportion of patients receiving chemotherapy without compromising recurrence-free survival, marking a landmark shift toward biomarker-driven precision oncology (Tie et al., 2022). Similarly, in muscle-invasive bladder cancer, the detection of ctDNA post-cystectomy in the IMvigor010 study identified patients with a profound survival benefit from adjuvant atezolizumab, while ctDNA-negative patients derived no benefit, underscoring the predictive power of this biomarker (Powles et al., 2021).

Beyond MRD, the most ambitious application of ctDNA technology is in multi-cancer early detection (MCED). These tests utilize targeted methylation sequencing, fragmentomic patterns, and mutational signatures to simultaneously detect dozens of cancer types from a single blood sample and, critically, predict the tissue of origin. The Circulating Cell-free Genome Atlas (CCGA) study demonstrated the feasibility of this approach, with a highly specific methylation-based assay achieving a false-positive rate of less than 1% and accurate tissue-of-origin prediction in 93% of true-positive cases (Liu et al., 2020). A large-scale prospective interventional study, the PATHFINDER trial, further validated this concept in a real-world population, finding that 1.4% of participants had a cancer signal detected, with a positive predictive value of 38%, which increased to over 98% when a cancer signal was confirmed to originate from a specific tissue (Klein et al., 2022). These results have ignited intense hope for population-scale screening, particularly for high-mortality cancers like pancreatic, ovarian, and liver cancers that lack conventional screening modalities. However, significant challenges remain, including the detection of early-stage (stage I) tumors, the biological origin of signals that resolve without a clinical cancer diagnosis, and the economic and psychological burden of false-positive results (Beer et al., 2021).

2.2 Circulating Tumor Cells and Exosomes: Complementary Windows into Metastasis

While ctDNA reflects tumor genomic architecture, CTCs provide a unique window into the metastatic cascade. As intact, viable cells that have invaded the vasculature, CTCs can be enumerated and characterized for their proteomic, transcriptomic, and secretory profiles (Alix-Panabières & Pantel, 2021). The CellSearch system, which remains the only FDA-cleared CTC enumeration platform, has established the prognostic value of CTC counts in metastatic breast, prostate, and colorectal cancers, with a baseline count of ≥5 cells per 7.5 mL of blood consistently correlating with worse progression-free and overall survival (Cristofanilli et al., 2019). However, the next frontier is CTC characterization. Single-cell sequencing of CTCs has revealed significant heterogeneity in actionable mutations, such as those in the androgen receptor in prostate cancer or in ESR1 in breast cancer, which may not be captured by a single-site tissue biopsy. This capability allows for the identification of emergent drug resistance mechanisms in real-time, guiding treatment adaptation (Miyamoto et al., 2015).

Extracellular vesicles, particularly exosomes (30-150 nm diameter), represent a third pillar of the liquid biopsy. These lipid bilayer-delimited particles carry a cargo of nucleic acids (mRNA, miRNA, lncRNA), proteins, and lipids that mirror the metabolic and signaling state of their parent cells. Their phospholipid membrane provides a protected microenvironment, making their cargo remarkably stable in circulation, an advantage over free-circulating nucleic acids (Kalluri & LeBleu, 2020). In pancreatic ductal adenocarcinoma (PDAC), a disease notorious for late diagnosis, a signature combining exosomal glypican-1 (GPC1) and specific miRNAs has shown promise in distinguishing early-stage PDAC from benign pancreatic diseases and healthy controls, a critical unmet need given the asymptomatic nature of resectable disease (Melo et al., 2015). Exosomal PD-L1 has also emerged as a potential predictive biomarker for immunotherapy, as tumor-derived exosomes carrying PD-L1 on their surface can suppress T-cell function systemically, and a reduction in exosomal PD-L1 levels during anti-PD-1 therapy may predict a clinical response before radiographic changes are evident (Chen et al., 2018). The clinical utility of exosomes, however, is currently limited by a lack of standardization in isolation and purification techniques, which vary from ultracentrifugation to size-exclusion chromatography and immunocapture, leading to heterogeneous results across studies (Théry et al., 2018). Figure 2 summarizes the clinical workflow illustrating liquid biopsy applications in oncology. Circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes obtained from peripheral blood are analyzed using advanced molecular techniques to support early cancer detection, minimal residual disease monitoring, mutation profiling, and personalized treatment selection.



Figure 2. Clinical Workflow of Liquid Biopsy in Precision Oncology

3. Neurodegenerative Diseases: The Age of Blood-Based Brain Biomarkers

For decades, the definitive diagnosis of Alzheimer's disease (AD) was a post-mortem histopathological exercise. The advent of CSF biomarkers (Aβ42, total tau, phospho-tau) and amyloid PET imaging allowed for in vivo diagnosis, but these modalities are hampered by invasiveness, high cost, and limited availability, restricting their use primarily to specialist centers and clinical trials (Jack Jr et al., 2018). The last half-decade has witnessed a seismic breakthrough: the development of ultrasensitive blood-based assays that can accurately reflect cerebral amyloid and tau pathology. This transformation is driven by technological innovations such as single-molecule array (Simoa), immunoprecipitation-mass spectrometry (IP-MS), and high-sensitivity immunoassays that can detect brain-derived proteins in the femtomolar concentration range in the presence of a vast excess of peripheral proteins (Zetterberg & Blennow, 2021).

3.1 Phospho-Tau as a Diagnostic and Prognostic Cornerstone

The microtubule-associated protein tau undergoes hyperphosphorylation at multiple residues in AD, leading to its aggregation into neurofibrillary tangles. The measurement of specific phospho-tau (p-tau) species in blood has emerged as the most transformative biomarker for AD. P-tau217, in particular, has demonstrated exceptional diagnostic accuracy, rivaling that of CSF and PET biomarkers. In the Arizona APOE Cohort Study, plasma p-tau217 distinguished neuropathologically defined AD from non-AD dementias with an area under the curve (AUC) of 0.98, a performance far superior to plasma p-tau181 and neurofilament light chain (NfL) (Palmqvist et al., 2020). Remarkably, plasma p-tau217 levels begin to increase before tau-PET signal is detectable, suggesting that changes in tau phosphorylation and secretion are very early, possibly reversible, events in the AD cascade (Janelidze et al., 2020). This temporal profile positions plasma p-tau217 as a critical biomarker for staging preclinical AD and identifying candidates for disease-modifying therapies, such as anti-amyloid monoclonal antibodies, before substantial neurodegeneration has occurred. The recent clinical approval of lecanemab and donanemab, therapies that require confirmation of amyloid pathology, has catapulted blood-based p-tau217 assays from a research curiosity to a central pillar of diagnostic triage, drastically reducing the need for confirmatory PET scans (Cummings et al., 2023).

P-tau181, while slightly less specific to AD than p-tau217, also provides significant clinical utility. Longitudinal aging studies have shown that plasma p-tau181 can predict future tau-PET positivity and cognitive decline up to eight years before symptom onset, marking a trajectory from normal cognition to mild cognitive impairment (Karikari et al., 2020). The A4 (Anti-Amyloid Treatment in Asymptomatic Alzheimer's) trial demonstrated that in cognitively unimpaired individuals with elevated brain amyloid, baseline plasma p-tau181 levels were predictive of neocortical tau pathology and subsequent cognitive decline, underscoring its prognostic value in the preclinical stage (Sperling et al., 2020). The differential kinetics of p-tau217 and p-tau181—with p-tau217 appearing earlier and more closely mapping to amyloid plaque accumulation—suggest a future diagnostic workflow where a highly sensitive p-tau217 test acts as a first-line screening tool, followed by more specific confirmatory assays if needed.

3.2 Neurofilament Light and Glial Fibrillary Acidic Protein: Markers of Neurodegeneration and Neuroinflammation

Neurofilament light chain (NfL) is a cytoplasmic protein highly expressed in large-caliber myelinated axons. Its release into the CSF and blood is a generic yet highly sensitive marker of neuroaxonal injury, irrespective of the cause. Unlike p-tau, which is disease-specific, plasma NfL is elevated across a spectrum of neurological conditions, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and traumatic brain injury (Bridel et al., 2019). This lack of specificity precludes its use as a standalone diagnostic for AD, but makes it an invaluable tool for prognosis, disease monitoring, and treatment response assessment in neurology at large. In MS, serum NfL levels correlate with the number of new T2 and gadolinium-enhancing lesions on MRI and predict future brain volume loss. Consequently, it has been proposed as a sensitive, blood-based endpoint in phase II clinical trials to screen the efficacy of novel disease-modifying therapies before committing to larger phase III studies with MRI endpoints (Kuhle et al., 2019). In ALS, elevated baseline serum NfL is a strong independent predictor of shorter survival and faster functional decline, aiding in patient stratification for clinical trials and empowering neurologists to provide more accurate prognostic counseling (Benatar et al., 2023).

Glial fibrillary acidic protein (GFAP), an intermediate filament protein of astrocytes, reflects a distinct pathological process: neuroinflammation and reactive astrogliosis. Plasma GFAP has been shown to be an early marker of emerging amyloid-β pathology, potentially preceding significant tau aggregation and even p-tau181 changes. In the Wisconsin Registry for Alzheimer's Prevention, plasma GFAP levels were elevated in individuals with preclinical AD and were associated with abnormal amyloid PET scans, independent of tau pathology (Benedet et al., 2021). This finding suggests that astrocytic activation is an early response to amyloid deposition, positioning plasma GFAP as a complementary biomarker to p-tau, potentially delineating an inflammatory stage of early AD that is distinct from the neurodegenerative phase tracked by NfL. The integration of these "A/T/N" (Amyloid, Tau, Neurodegeneration) biomarkers in blood promises to provide a comprehensive, low-cost, and scalable staging system for AD, analogous to the TNM staging in oncology.

4. Cardiovascular and Metabolic Risk Reclassification

Cardiovascular disease (CVD) remains the leading cause of global mortality, a statistic that underscores the inadequacy of current primary prevention strategies. The reliance on traditional risk factors, such as the Framingham Risk Score or the Pooled Cohort Equations, generates probabilistic assessments that fail to capture individual biological susceptibility. The integration of circulating and genomic biomarkers is creating a new paradigm of precision cardiology, moving beyond risk prediction to risk reclassification and the identification of preclinical disease states that demand intervention (Nayor et al., 2021).

4.1 High-Sensitivity Cardiac Troponins: Redefining Myocardial Injury

The development of high-sensitivity cardiac troponin (hs-cTn) assays has been one of the most consequential advances in cardiovascular diagnostics, directly translating into improved patient outcomes through faster rule-out protocols for acute myocardial infarction (AMI) in emergency departments (Neumann et al., 2019). However, its application in the primary prevention setting among asymptomatic individuals may prove even more far-reaching. Chronic, low-level myocardial injury, detectable only with hs-cTn assays, is remarkably common in the general population and is independently associated with structural heart disease, incident heart failure, and cardiovascular death (Welsh et al., 2018). In the Atherosclerosis Risk in Communities (ARIC) study, elevated hs-cTnI levels were detected in nearly a quarter of middle-aged adults and were predictive of incident coronary heart disease, heart failure hospitalization, and all-cause mortality over a 15-year follow-up, independent of traditional risk factors (Jia et al., 2019).

The clinical actionability of this information is now being tested. The recently concluded WESTCOR-Primary prevention trial demonstrated that incorporating hs-cTnI into a screening algorithm, alongside coronary artery calcium (CAC) scoring, significantly improved the reclassification of individuals into risk categories that would modify lipid-lowering therapy eligibility (Tang et al., 2021). An individual with an intermediate risk score but an elevated hs-cTnI level is effectively reclassified as high-risk, a status that warrants aggressive LDL-cholesterol lowering that would not typically be indicated based on population-derived risk calculators alone. Moreover, a dynamic concept of cardiovascular health is emerging, where changes in hs-cTn over time, rather than a single baseline measurement, provide a more nuanced risk assessment. A rise in serial hs-cTn measurements predicts adverse outcomes even if levels remain within the conventional "normal" range, reflecting a trajectory of active, ongoing myocardial stress (Berry et al., 2021).

4.2 Natriuretic Peptides and Polygenic Risk Scores

The natriuretic peptide system, specifically B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP), is a critical counter-regulatory mechanism against cardiac wall stress and volume overload. While central to the diagnosis of heart failure in symptomatic patients, their role in presymptomatic screening is gaining momentum. The STOP-HF trial demonstrated that screening asymptomatic adults at risk for heart failure with NT-proBNP, followed by collaborative care with a cardiologist-supervised natriuretic peptide-guided management protocol, reduced the prevalence of left ventricular systolic dysfunction and symptomatic heart

failure (Ledwidge et al., 2013). Building on this, the PONTIAC study and the more robust PARADIGM-HF sub-analyses have consolidated the concept that pharmacological modulation of the natriuretic peptide system, using sacubitril/valsartan, is most beneficial in patients with elevated baseline NT-proBNP, providing a predictive biomarker framework for targeted therapy (Januzzi et al., 2019). This biology-first approach, guided by a circulating marker of hemodynamic stress, is a template for preventing heart failure before the onset of irreversible remodeling.

In parallel, the proliferation of genome-wide association studies (GWAS) has crystallized the genetic architecture of complex cardiovascular traits into polygenic risk scores (PRS). A PRS aggregates the effects of millions of common genetic variants into a single, normally distributed risk score. For coronary artery disease (CAD), a PRS has been shown to predict risk with an effect size comparable to traditional risk factors and, crucially, to identify individuals who derive the greatest relative and absolute benefit from statin therapy (Khera et al., 2018). In a seminal analysis from the UK Biobank, individuals with a high CAD PRS had a lifetime risk equivalent to that of familial hypercholesterolemia mutation carriers, yet most were undiagnosed and untreated under standard care. The integration of high PRS with elevated hs-cTn or BNP identifies a particularly vulnerable cohort, where multiple biological pathways converge on a high-risk state. This multi-modal biomarker strategy—combining a stable genetic scaffold (PRS) with dynamic circulating markers of subclinical injury (hs-cTn) and stress (NT-proBNP)—represents the pinnacle of precision prevention, creating a comprehensive and lifelong risk profile from a single blood sample (Mosley et al., 2020).

5. The Challenge of Clinical Implementation and Interpretation

The scientific breakthroughs in biomarker discovery have outpaced the healthcare system's ability to implement them rationally and equitably. The translation of a biomarker from analytical validity to clinical utility is a steep and often brutal gauntlet, littered with discarded discoveries. The key bottlenecks are no longer in the wet lab; they reside in the domains of biostatistics, regulation, economics, and ethics. The principal systemic challenges that impede this translation, along with their consequences and proposed mitigation strategies, are systematically summarized in Table 2.

Table 2. Key Systemic Challenges and Ethical Considerations in Biomarker Implementation

Challenge Domain	Specific Challenge	Consequence for Clinical Implementation	Proposed Mitigation Strategy & Key References
Analytical & pre-analytical	Lack of standardization across assay platforms (e.g., different p-tau immunoassays); absence of certified reference materials.	Non-interchangeable results; invalid meta-analyses; inability to establish universal clinical cut-offs.	Develop harmonized reference methods and materials (JCTLM); enforce strict pre-analytical protocols (Verberk et al., 2020; Dayon et al., 2022).
Interpretive Complexity	"Black box" machine learning algorithms for multi-omics and MCED tests; overfitting to training datasets.	Physician mistrust; regulatory hurdles; failure to generalize to real-world populations.	Develop explainable AI (XAI) for transparent logic; rigorous external validation in diverse biobanks before clinical use (Arrieta et al., 2020).
Clinical Utility	Biomarker detects disease for which no effective intervention exists, or leads to diagnosis of indolent pathology.	Overdiagnosis and overtreatment (e.g., indolent cancer signal of unknown primary); psychological harm to "worried well."	Couple detection biomarkers with prognostic biomarkers of aggression; pragmatic RCTs measuring hard outcomes (disease-specific mortality) (Welch & Black, 2010).
Ethical and Psychosocial	Psychological burden of preclinical disease labeling; genetic/privacy discrimination risk.	Anxiety, altered self-perception, insurability concerns (life, long-term care); widening health disparities.	Mandate pre-/post-test counseling; modernize anti-discrimination laws (GINA) to cover non-health insurance; ensure equitable, affordable access (Largent et al., 2021; Rothstein, 2021).
Economic	High cost of multi-omics profiling and complex downstream diagnostic cascades.	Limited to affluent populations; fails to prove cost-effectiveness against standard care.	Value-based pricing models; health technology assessments measuring cost per quality-adjusted life year (QALY) gained from early vs. late-stage intervention.

5.1 The Multi-Marker Conundrum and Algorithmic Diagnosis

Single-biomarker diagnostics are giving way to complex multi-analyte panels, a transition that brings immense promise but profound interpretive challenges. The sheer dimensionality of modern omics data, where thousands of variables are measured across hundreds of patients, creates a high-dimensional statistical space that is highly prone to overfitting and false discovery unless rigorous methodologies are applied (Broadhurst et al., 2018). Machine learning models, particularly deep learning architectures, are increasingly employed to parse these complex datasets, identifying patterns that serve as composite diagnostic signatures. For example, in the development of MCED tests, a methylation-based classifier is trained on tens of thousands of cancer and non-cancer samples to learn a signature that distinguishes malignant and healthy cell-free DNA patterns, a task that is computationally irreducible to human logic (Liu et al., 2020). While powerful, these 'black box' algorithms create a challenge for physician trust and regulatory oversight. The clinician is asked to act on a probability score derived from a model whose internal logic is opaque, transforming the practice of medicine from an interpretive to a probabilistic exercise. The emerging field of explainable AI (XAI) seeks to bridge this gap by generating post-hoc explanations for model predictions, such as highlighting which specific biomarkers most heavily influenced a positive cancer signal call, thereby providing a pathway for clinical validation (Arrieta et al., 2020).

5.2 Standardization and Real-World Performance

The translation of a biomarker assay from a single high-performing research laboratory to a globally distributed, scalable clinical test is a monumental challenge. Analytical preconditions such as pre-analytical sample handling, tube type, centrifugation protocols, and freeze-thaw stability dramatically affect the measurement of fragile analytes like extracellular vesicles and phospho-tau proteins (Verberk et al., 2020). The lack of international reference standards and certified reference materials for the vast majority of novel protein biomarkers means that results from different immunoassay platforms are often not interchangeable, generating divergent absolute values and clinical cut-offs for the same biomarker (Dayon et al., 2022). This analytical chaos undermines the evidence base, as meta-analyses of diagnostic accuracy collapse studies with incompatible measurement units. Efforts like the Joint Committee for Traceability in Laboratory Medicine (JCTLM) are beginning to address this for high-priority markers, but the pace of standardization lags far behind the pace of discovery. Consequently, the 'real-world' performance of a biomarker test deployed in a community hospital can be significantly inferior to its performance in the expert academic center where it was originally developed, a phenomenon that dampens clinical enthusiasm and dilutes the public health impact (Hrudey et al., 2022).

6. Multi-Omics and the Taxonomy of Pre-Disease

The future of early disease detection lies not in the refinement of individual biomarkers, but in the holistic integration of multiple layers of biological information—a true multi-omics synthesis. The human body is a complex system of interacting networks, and the transition from health to disease is a state change that likely involves coordinated, simultaneous perturbations in the genome, transcriptome, proteome, metabolome, and microbiome (Chen et al., 2012). A seminal proof-of-concept study demonstrated that deep longitudinal profiling of an individual, combining genomics, plasma proteomics, metabolomics, and gut microbiome data, could identify personalized disease triggers and detect the onset of type 2 diabetes, viral infection, and myocardial stress weeks or months before standard clinical diagnosis (Schüssler-Fiorenza Rose et al., 2019). This "personal dense, dynamic data cloud" generates a far more sensitive and specific signal than any single marker alone.

This vision has been scaled to large population cohorts. Multi-omics phenotyping of healthy blood donors has uncovered that a substantial fraction of the "healthy" population carries molecular signatures of preclinical disease. For instance, deep proteomic analysis can identify individuals with subtle organ-specific aging trajectories, where a person's kidney proteome might look decades older than their chronological age, correlating with subsequent development of hypertension and kidney disease (Oh et al., 2023). The concept of an "immune health score," derived from deep immune phenotyping and cell-free DNA methylation, is being explored to identify individuals at high risk for severe infections or sub-optimal vaccine responses before exposure, a concept that gained immense urgency during the COVID-19 pandemic (Ahern et al., 2022). This transition from reactive diagnosis to proactive "health surveillance" will fundamentally change the patient-clinician interaction. The annual wellness visit may be transformed into a data-driven review of a multi-omic dashboard, where deviations from an individual's baseline—their personal cloud of molecular normalcy—trigger investigation, rather than population-based thresholds.

This future, however, is contingent on a massive overhaul of clinical trial design. Demonstrating that a multi-omics-guided pre-emptive intervention improves life expectancy or reduces the incidence of advanced disease requires large, decade-spanning, adaptive platform trials. The economic viability, too, requires proof that the cost of broad profiling and early intervention is offset by the downstream avoidance of catastrophic care costs for end-stage disease. The convergence of technologies is thus not a concluding chapter, but a prologue to a new scientific discipline of anticipatory medicine. Figure 3 shows the integrated clinical decision pathway demonstrating how laboratory biomarkers from oncology, neurology, cardiovascular medicine, and infectious diseases are combined with artificial intelligence to guide early diagnosis, risk stratification, disease monitoring, and personalized therapeutic interventions, supporting precision healthcare.



Figure 3. Biomarker-Guided Clinical Decision Pathway for Precision Healthcare

7. Ethical and Societal Dimensions of Early Detection

The power to detect a disease before it manifests is a double-edged sword, carrying weighty ethical implications that transcend the technicalities of assay performance. Identifying a latent pathology in an asymptomatic individual transforms their identity from a healthy person into a patient-in-waiting, a state often described as the "worried well" (Banda, 2015). This label imposes a psychological burden of anxiety, hypervigilance, and a changed self-perception, even in the absence of any physical suffering. For conditions like Alzheimer's disease, where disease-modifying therapies have only recently shown modest clinical efficacy and are restricted to specific stages, the knowledge of one's preclinical amyloid or tau positivity carries a profound emotional weight. Studies on the disclosure of AD biomarker status in cognitively normal individuals reveal a nuanced landscape, where most participants do not experience long-term psychological harm, but a subset of those who test positive report significant distress and a heightened focus on memory lapses (Largent et al., 2021). This necessitates robust pre- and post-test counseling infrastructure, a resource that is wholly absent from most primary care settings.

The ethical challenge is amplified in the domain of MCED testing. A positive MCED result activates a cascade of whole-body diagnostic imaging, often including PET-CT, to locate an occult primary tumor. This leads to two problematic scenarios. The first is the management of a positive cancer signal for which no anatomical tumor can be found, a state of indefinite surveillance with significant psychological morbidity and radiation exposure. The second, and more fundamental, is the problem of overdiagnosis: the detection of a biologically indolent cancer that would never have caused symptoms or death within the patient's natural lifetime (Welch & Black, 2010). The prostate-specific antigen (PSA) screening saga serves as a cautionary tale, where the biomarker's adoption without a clear framework for discriminating lethal from indolent disease led to extensive overtreatment and harm. To avoid this fate, MCED tests must be accompanied by orthogonal second-generation biomarkers—such as ctDNA fragmentomic patterns or tumor microenvironment proteomics—that can predict biological aggression and not just anatomical presence.

Finally, the genomic privacy and data governance challenges are monumental. A comprehensive multi-omic profile is the ultimate personally identifiable information, a molecular diary that reveals current health, future disease trajectories, behavioral traits, and even ancestral and familial secrets. Insurance discrimination, despite legislative safeguards like the Genetic Information Nondiscrimination Act (GINA) in the United States, remains a potent concern for patients, particularly as these laws do not cover long-term care or life insurance (Rothstein, 2021). Ensuring equitable access to these transformative technologies is a moral imperative. If the benefits of early detection, from MCED to Alzheimer's screening, accrue only to affluent populations with comprehensive health insurance, the result will be a widening of health disparities, creating a biological underclass whose diseases are detected only when symptomatic, late, and at great cost to systems and dignity.

8. CONCLUSION

This period has been an era of unprecedented advances in the discovery and clinical translation of laboratory biomarkers, definitively ending an era of therapeutic nihilism about early disease detection. We have moved from measuring a few static biochemical indices to decoding the dynamic, multi-dimensional molecular language of presymptomatic pathology. Liquid biopsies have provided a non-invasive portal into solid tumor biology, enabling

a future where cancer screening and monitoring are as routine as a cholesterol check. Blood-based phospho-tau assays have promised to dismantle the diagnostic bottleneck in Alzheimer's disease, democratizing access to a precision diagnosis that was once the preserve of academic memory clinics. High-sensitivity cardiovascular markers are rewriting the calculus of primary prevention, identifying subclinical injury and stress years before heart failure or infarction become clinically apparent.

Yet, these triumphs of discovery are shadowed by the immense complexity of their integration into a humane and effective healthcare delivery model. The promise of multi-omics and AI-driven diagnostics risks creating a labyrinthine, expensive, and anxiety-generating system that benefits the worried well while failing to reach the underserved. The ultimate bottleneck is not technological but cognitive and systemic. The future success of this revolution will not be measured by the sensitivity of a p-tau217 assay or the methylation pattern of a ctDNA fragment, but by our collective ability to weave these data threads into a new narrative—one of anticipatory health. This requires a concerted effort to standardize assays, design pragmatic clinical trials that demonstrate patient-centered outcomes, develop an ethical framework for managing pre-disease, and reimagine the physician's role as an interpreter of a continuous biometric stream. The biomarker age is not merely providing new tests; it is demanding a new philosophy of medicine, one that defines health not as the absence of diagnosed disease, but as the successful, lifelong management of a unique and dynamic molecular ecosystem.

REFERENCES

1. Ahern, D. J., Ai, Z., Ainsworth, M., Allan, C., Allcock, A., Angus, B., ... & Salio, M. (2022). A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. *Cell*, *185*(5), 916-938.
2. Alix-Panabières, C., & Pantel, K. (2021). Liquid biopsy: from discovery to clinical application. *Cancer discovery*, *11*(4), 858-873.
3. Arrieta, A. B., Díaz-Rodríguez, N., Del Ser, J., Bennetot, A., Tabik, S., Barbado, A., ... & Herrera, F. (2020). Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI. *Information fusion*, *58*, 82-115.
4. Ashley, E. A. (2016). Towards precision medicine. *Nature Reviews Genetics*, *17*(9), 507-522.
5. Banda, J. (2015). Rapid home HIV testing: risk and the moral imperatives of biological citizenship. *Body & Society*, *21*(4), 24-47.
6. Beer, T. M., McDonnell, C. H., Nadauld, L., Liu, M. C., Klein, E. A., Reid, R. L., ... & Schrag, D. (2021). Interim results of PATHFINDER, a clinical use study using a methylation-based multi-cancer early detection test. *J Clin Oncol*, *39*(15_suppl), 3010-3010.
7. Benatar, M., Wuu, J., & Turner, M. R. (2023). Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. *Brain*, *146*(7), 2711-2716.
8. Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., ... & Suárez-Calvet, M. (2021). Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. *JAMA neurology*, *78*(12), 1471-1483.
9. Berry, J. D., Nambi, V., Ambrosius, W. T., Chen, H., Killeen, A. A., Taylor, A., ... & De Lemos, J. A. (2021). Associations of high-sensitivity troponin and natriuretic peptide levels with outcomes after intensive blood pressure lowering: findings from the SPRINT randomized clinical trial. *JAMA cardiology*, *6*(12), 1397-1405.
10. Bridel, C., Van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., Nfl Group, ... & Wild, E. J. (2019). Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. *JAMA neurology*, *76*(9), 1035-1048.
11. Broadhurst, D., Goodacre, R., Reinke, S. N., Kuligowski, J., Wilson, I. D., Lewis, M. R., & Dunn, W. B. (2018). Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. *Metabolomics*, *14*(6), 72.
12. Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., ... & Guo, W. (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature*, *560*(7718), 382-386.
13. Chen, R., Mias, G. I., Li-Pook-Than, J., Jiang, L., Lam, H. Y., Chen, R., ... & Snyder, M. (2012). Personal omics profiling reveals dynamic molecular and medical phenotypes. *Cell*, *148*(6), 1293-1307.
14. Cristofanilli, M., Pierga, J. Y., Reuben, J., Rademaker, A., Davis, A. A., Peeters, D. J., ... & Pantel, K. (2019). The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. *Critical reviews in oncology/hematology*, *134*, 39-45.
15. Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., ... & Salloway, S. (2023). Lecanemab: appropriate use recommendations. *The journal of prevention of Alzheimer's disease*, *10*(3), 362-377.
16. Dayon, L., Cominetti, O., & Affolter, M. (2022). Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications. *Expert review of proteomics*, *19*(2), 131-151.
17. Gorgannezhad, L., Umer, M., Islam, M. N., Nguyen, N. T., & Shiddiky, M. J. (2018). Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. *Lab on a Chip*, *18*(8), 1174-1196.
18. Hansson, O., Edelmayer, R. M., Boxer, A. L., Carrillo, M. C., Mielke, M. M., Rabinovici, G. D., ... & Teunissen, C. E. (2022). The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. *Alzheimer's & Dementia*, *18*(12), 2669-2686.

19. Hrudey, S. E., Bischel, H. N., Charrois, J., Chik, A. H., Conant, B., Delatolla, R., ... & Sikora, C. (2022). Wastewater surveillance for SARS-CoV-2 RNA in Canada. *Facets*.
20. Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021). Liquid biopsy enters the clinic—implementation issues and future challenges. *Nature reviews Clinical oncology*, *18*(5), 297-312.
21. Jack Jr, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., ... & Silverberg, N. (2018). NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's & dementia*, *14*(4), 535-562.
22. Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., ... & Hansson, O. (2020). Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nature medicine*, *26*(3), 379-386.
23. Januzzi Jr, J. L., Prescott, M. F., Butler, J., Felker, G. M., Maisel, A. S., McCague, K., ... & Solomon, S. D. (2019). Association of change in N-terminal pro–B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. *Jama*, *322*(11), 1085-1095.
24. Jia, X., Sun, W., Hoogeveen, R. C., Nambi, V., Matsushita, K., Folsom, A. R., ... & Ballantyne, C. M. (2019). High-sensitivity troponin I and incident coronary events, stroke, heart failure hospitalization, and mortality in the ARIC study. *Circulation*, *139*(23), 2642-2653.
25. Kalluri, R., & LeBleu, V. S. (2020). The biology, function, and biomedical applications of exosomes. *science*, *367*(6478), eaau6977.
26. Karczewski, K. J., & Snyder, M. P. (2018). Integrative omics for health and disease. *Nature Reviews Genetics*, *19*(5), 299-310.
27. Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., ... & Blennow, K. (2020). Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *The Lancet Neurology*, *19*(5), 422-433.
28. Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., ... & Kathiresan, S. (2018). Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nature genetics*, *50*(9), 1219-1224.
29. Klein, E. A., Tomasz, M., & Beer, T. M. (2022, October). A prospective study of a multi cancer early detection blood test in a clinical practice setting. In *Poster presented at: Li-Fraumeni Syndrome (LFS) Association Symposium*.
30. Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., ... & Kappos, L. (2019). Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. *Neurology*, *92*(10), e1007-e1015.
31. Largent, E. A., Stites, S. D., Harkins, K., & Karlawish, J. (2021). 'That would be dreadful': The ethical, legal, and social challenges of sharing your Alzheimer's disease biomarker and genetic testing results with others. *Journal of Law and the Biosciences*, *8*(1), lsab004.
32. Ledwidge, M., Gallagher, J., Conlon, C., Tallon, E., O'Connell, E., Dawkins, I., ... & McDonald, K. (2013). Natriuretic peptide–based screening and collaborative care for heart failure: the STOP-HF randomized trial. *Jama*, *310*(1).
33. Liu, M. C., Oxnard, G. R., Klein, E. A., Swanton, C. S. M. C. C., Seiden, M. V., Liu, M. C., ... & Youngren, J. (2020). Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Annals of Oncology*, *31*(6), 745-759.
34. Melo, S. A., Luecke, L. B., Kahlert, C., Fernandez, A. F., Gammon, S. T., Kaye, J., ... & Kalluri, R. (2015). Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature*, *523*(7559), 177-182.
35. Miyamoto, D. T., Zheng, Y. U., Wittner, B. S., Lee, R. J., Zhu, H., Broderick, K. T., ... & Haber, D. A. (2015). RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. *Science*, *349*(6254), 1351-1356.
36. Mosley, J. D., Gupta, D. K., Tan, J., Yao, J., Wells, Q. S., Shaffer, C. M., ... & Wang, T. J. (2020). Predictive accuracy of a polygenic risk score compared with a clinical risk score for incident coronary heart disease. *Jama*, *323*(7), 627-635.
37. Nayor, M., Brown, K. J., & Vasan, R. S. (2021). The molecular basis of predicting atherosclerotic cardiovascular disease risk. *Circulation research*, *128*(2), 287-303.
38. Neumann, J. T., Twerenbold, R., Ojeda, F., Sörensen, N. A., Chapman, A. R., Shah, A. S., ... & Blankenberg, S. (2019). Application of high-sensitivity troponin in suspected myocardial infarction. *New England Journal of Medicine*, *380*(26), 2529-2540.
39. Oh, H. S. H., Rutledge, J., Nachun, D., Pálovics, R., Abiose, O., Moran-Losada, P., ... & Wyss-Coray, T. (2023). Organ aging signatures in the plasma proteome track health and disease. *Nature*, *624*(7990), 164-172.
40. Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., ... & Hansson, O. (2020). Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. *Jama*, *324*(8), 772-781.
41. Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., ... & Mariathasan, S. (2021). ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. *Nature*, *595*(7867), 432-437.

42. Rothstein, M. A. (2021). Big data, surveillance capitalism, and precision medicine: challenges for privacy. *Journal of Law, Medicine & Ethics*, *49*(4), 666-676.
43. Schüssler-Fiorenza Rose, S. M., Contrepois, K., Moneghetti, K. J., Zhou, W., Mishra, T., Mataraso, S., ... & Snyder, M. P. (2019). A longitudinal big data approach for precision health. *Nature medicine*, *25*(5), 792-804.
44. Sperling, R. A., Donohue, M. C., Raman, R., Sun, C. K., Yaari, R., Holdridge, K., ... & Aisen, P. S. (2020). Association of factors with elevated amyloid burden in clinically normal older individuals. *JAMA neurology*, *77*(6), 735-745.
45. Tang, O., Matsushita, K., Coresh, J., Hoogeveen, R. C., Windham, B. G., Ballantyne, C. M., & Selvin, E. (2021). High-sensitivity cardiac troponin I for risk stratification in older adults. *Journal of the American Geriatrics Society*, *69*(4), 986-994.
46. Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., ... & Jovanovic-Talisman, T. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *Journal of extracellular vesicles*, *7*(1), 1535750.
47. Tie, J., Cohen, J. D., Lahouel, K., Lo, S. N., Wang, Y., Kosmider, S., ... & Gibbs, P. (2022). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. *New England Journal of Medicine*, *386*(24), 2261-2272.
48. Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. *Nature medicine*, *25*(1), 44-56.
49. Verberk, I. M., Thijssen, E., Koelewijn, J., Mauroo, K., Vanbrabant, J., De Wilde, A., ... & Teunissen, C. E. (2020). Combination of plasma amyloid beta (1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. *Alzheimer's research & therapy*, *12*(1), 118.
50. Wan, J. C., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., ... & Rosenfeld, N. (2017). Liquid biopsies come of age: towards implementation of circulating tumour DNA. *Nature Reviews Cancer*, *17*(4), 223-238.
51. Welch, H. G., & Black, W. C. (2010). Overdiagnosis in cancer. *Journal of the National Cancer Institute*, *102*(9), 605-613.
52. Welsh, P., Preiss, D., Shah, A. S., McAllister, D., Briggs, A., Boachie, C., ... & Sattar, N. (2018). Comparison between high-sensitivity cardiac troponin T and cardiac troponin I in a large general population cohort. *Clinical chemistry*, *64*(11), 1607-1616.
53. Zeller, T., Ojeda, F., Brunner, F. J., Peitsmeyer, P., Münzel, T., Binder, H., ... & Lackner, K. J. (2015). High-sensitivity cardiac troponin I in the general population–defining reference populations for the determination of the 99th percentile in the Gutenberg Health Study. *Clinical Chemistry and Laboratory Medicine (CCLM)*, *53*(5), 699-706.
54. Zetterberg, H., & Blennow, K. (2021). Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. *Molecular neurodegeneration*, *16*(1), 10.

النهضة الجزيئية: التطورات الحديثة في تقنيات تشخيص الأمراض المعدية

الملخص

شهد المشهد العالمي لتشخيص الأمراض المعدية تحولاً عميقاً، مبتعداً عن الطرق البطيئة القائمة على الاستزراع إلى تقنيات جزيئية سريعة وعالية الحساسية. تقوم هذه المراجعة السردية بتجميع التطورات الحديثة من عام 2015 إلى عام 2026، مستكشفةً كيف أحدثت الابتكارات مثل تسلسل الجيل التالي(NGS) ، ومنصات كريسبر (CRISPR) المتقدمة، والتفاعل البوليميرازي المتسلسل الرقمي (dPCR) ثورة في الكشف عن مسببات الأمراض. ندرس الدور المحوري لهذه التقنيات خلال جائحة كوفيد-19، والذي أدى إلى تسريع تطوير واعتماد الاختبارات الجزيئية في نقطة الرعاية (POC)ولوحات المتلازمات المتعددة. لقد عزز دمج الذكاء الاصطناعي مع البيانات الجينومية التنبؤ بمقاومة مضادات الميكروبات وتتبع تفشي الأمراض، في حين أضفت طرق التضخيم متساوي الحرارة الجديدة الطابع الديمقراطي على الوصول إلى الاختبارات في البيئات محدودة الموارد. من خلال تقييم الفائدة السريرية والقيود والمسار المستقبلي لهذه الأدوات، تسلط هذه المراجعة الضوء على تحول نموذجي نحو نموذج تشخيصي لامركزي قائم على البيانات، وهو أمر ضروري للطب الدقيق والأمن الصحي العالمي. إن التقارب بين علم الجينوم والموائع الدقيقة والتعلم الآلي لا يقتصر على تحسين التشخيص فحسب؛ بل إنه يعيد تشكيل نهجنا بشكل أساسي في إدارة الأمراض المعدية.

الكلمات المفتاحية :تسلسل الجيل التالي، تشخيصات كريسبر، الاختبار في نقطة الرعاية، التفاعل البوليميرازي المتسلسل الرقمي، مقاومة مضادات الميكروبات.